tradingkey.logo

BRIEF-Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

ReutersFeb 5, 2025 2:07 PM

- Shanghai Henlius Biotech Inc 2696.HK:

  • SERPLULIMAB APPROVED IN THE EU FOR FIRST-LINE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)

Source text: ID:nPn1dClhYa

Further company coverage: 2696.HK

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI